#USA #Draper #CenExel #Pain Task Force #Non-Opioid Therapy

Addressing Challenges in Pain Research

Pain management is a complex field fraught with unique challenges that differ significantly from many other therapeutic areas. Understanding this complexity, CenExel Clinical Research has taken proactive steps by establishing the Pain Task Force. This group comprises an alliance of pain researchers, investigators, and operational leaders who collaborate across CenExel’s comprehensive nationwide network.

The Complexity of Pain Management

Pain is a multifaceted condition, marked by intricate biological mechanisms and widespread variability among patients. Clinical trials in this arena often present substantial difficulties, including high placebo response rates. Recognizing these issues, the CenExel Pain Task Force aims to conduct high-quality clinical trials that not only expedite enrollment but also uphold integrity in the data collected.

Dr. Todd Bertoch, the Chief Medical Director of the Pain Task Force and Principal Investigator at CenExel Salt Lake City, emphasizes the vast challenges presented in pain studies. He states, “Minor variations in patient selection, site training, endpoint assessment, or protocol execution can significantly influence study outcomes. This highlights the immense importance of experience in this specialized field.”

Standardizing Practices to Enhance Outcomes

One of the pressing concerns for sponsors of pain studies is often the necessity for studies to span different research centers. This requires careful consideration, as variations in execution can detrimentally affect data quality. The Pain Task Force’s innovative approach addresses this concern by standardizing best practices across CenExel's research sites.

“We want sponsors to benefit from the quality of single-site data while still achieving the advantages of multi-site enrollment capabilities. By coordinating expertise across our network, we can minimize variability, enhance study execution, and produce the reliable data sponsors need to make informed decisions about advancing pain therapies,” Dr. Bertoch explains.

Experienced Investigators and Rigorous Execution

CenExel’s comprehensive capabilities in pain research have been developed through years of experience studying various pain conditions, including acute, chronic, neuropathic, and post-surgical pain. The network employs validated pain models and has backed the advancement of numerous investigative therapies that utilize a diverse range of mechanisms.

Dr. Josh Rothstein, a Principal Investigator for CenExel Atlanta, points out that bringing forward innovative pain therapies necessitates more than just the ability to enroll patients. “It requires experienced investigators, stringent study execution, and dedication to generating consistent, high-quality clinical data. Through the Pain Task Force, we create a framework for sharing expertise, standardizing best practices, and reducing undue variability, all of which assists in the advancement of impactful treatment options for patients,” he states.

About CenExel

CenExel stands as a premier and wholly owned clinical research site network committed to aiding the life sciences sector in discovering and developing transformative therapies. The organization provides exceptional research support in designing and executing complex clinical trials. With a foundation of scientific expertise, a roster of distinguished Principal Investigators, and advanced patient engagement strategies, CenExel emphasizes a focus on delivering accurate data and operational excellence.

Strategically positioned in major metropolitan areas, CenExel's Centers of Excellence have conducted thousands of studies with meticulous precision and efficiency. The organization’s relentless dedication to quality, the patient experience, and client success ensures favorable outcomes in clinical development.

In essence, CenExel’s proficiency and execution capabilities greatly enhance pharmaceutical and biotechnology companies' understanding of diseases, thus hastening clinical advancement and improving patient outcomes globally. For further information, visit CenExel Research.